Drug Name: Flibanserin
Drug Creator: Boehringer Ingelheim Pharmaceuticals
Clinical Trial ID: NCT00996164

Flibanserin’s effects are aimed at treating psychological dysfunctions of a sexual nature. It is currently undergoing part of the Phase III Clinical Trials with the Food and Drug Administration. A number of participants are taking Flibanserin, while another group is given a placebo. This helps test the actual effectiveness of the drug from an unbiased, objective standpoint, since participants do not know if they are actually taking the drug or not. This process labels the type of study as Interventional, which is the most common.

The design of the study aims to support the scientific method by randomly selecting participants who meet the necessary criteria, making the study double-blind and adding a parallel assignment, and finally, measuring the safety and efficacy of Flibanserin.

Flibanserin’s Phase III Clinical Trial lasts for approximately twenty-four weeks. It began in October of 2009 and ends in February of 2011. The length of the process is due to all the necessary finish touches, data analysis, etc.

The Clinical Trial for Flibanserin will test to see if the participants had an increase in sexually-satisfying experiences. Approximately 900 women between the ages of 18 and 55 are taking part in this study. Those who have been given Flibanserin are issued a 100 mg dosage.